Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? Insulin therapy has proven itself and is considered the mainstay of treatment

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 2112-2117

  Umpierrez, Guillermo E ^a   Korytkowski, Mary ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; INSULIN; LONG ACTING INSULIN; PLACEBO; SHORT ACTING INSULIN;

ARTICLE; CONGESTIVE HEART FAILURE; CONSTIPATION; DECREASED APPETITE; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN SENSITIVITY; INSULIN TREATMENT; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRACTICE GUIDELINE; SURGICAL PATIENT; TREATMENT RESPONSE; VOMITING;

DIABETES MELLITUS, TYPE 2; HUMANS; INCRETINS; RECEPTORS, GLUCAGON;

EID: 84885986031     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2233     Document Type: Article

References (26)

1. Swanson CM, Potter DJ, Kongable GL, Cook CB. An update on inpatient glycemic control in hospitals in the United States. Endocr Pract 2011;17:853-861
2. van den Berghe G, Wouters P, Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-1367
3. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemiarelated mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009;37:3001-3009
4. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978-982
5. Umpierrez GE, Smiley D, Jacobs S., et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34:256-261
6. Moghissi ES, Korytkowski MT, DiNardo M., et al.; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119-1131
7. Schnipper JL, Magee M, Larsen K, Inzucchi SE, Maynard G; Society of Hospital Medicine Glycemic Control Task Force. Society of Hospital Medicine Glycemic Control Task Force summary: practical recommendations for assessing the impact of glycemic control efforts. J HospMed 2008;3(Suppl.): 66-75
8. Umpierrez GE, Hellman R, Korytkowski MT., et al.; Endocrine Society.Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:16-38
9. Chaudhuri A, Dandona P, Fonseca V. Cardiovascular benefits of exogenous insulin. J Clin Endocrinol Metab 2012;97:3079-3091
10. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53:2079-2086
11. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P. Insulin inhibits the proinflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002;87: 1419-1422
12. Finfer S, Liu B, Chittock DR., et al.; NICESUGAR Study Investigators. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012;367:1108-1118
13. Meier JJ, Weyhe D, Michaely M., et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004;32:848-851
14. Müssig K, Oncü A, Lindauer P., et al. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008; 102:646-647
15. Nikolaidis LA, Mankad S, Sokos GG., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109: 962-965
16. Sokos GG, Bolukoglu H, German J., et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100:824-829
17. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699
18. Halbirk M, Nørrelund H, Møller N., et al.Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010;298:H1096-H1102
19. Mecott GA, Herndon DN, Kulp GA., et al. The use of exenatide in severely burned pediatric patients. Crit Care 2010;14: R153
20. Abuannadi M, Kosiborod M, Riggs L., et al. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract 2013;19:81-90
21. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-777
22. Monami M, Cremasco F, Lamanna C., et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a metaanalysis of randomized clinical trials. Exp Diabetes Res 2011;2011:215764
23. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011;34:369-374
24. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-485
25. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471
26. Dormuth CR, Carney G, Carleton B, Bassett K,Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009;169:1395-1402